Moreover, the CRISPR-Cas system can also be used to improve more traditional treatment methods, such as radiotherapy, by targeting and suppressing factors responsible for radio-resistance, such as focal adhesion kinase in KRAS-mutant cells or gene knockout, which might revert NSCLC cells to a radiosensitive phenotype (Leiser et al. 2021; Moreno Roig et al. 2019; Tang et al. 2016). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.